RecruitingPhase 1NCT07329101

Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis

Sponsor

Jiangsu vcare pharmaceutical technology co., LTD

Enrollment

10 participants

Start Date

Nov 11, 2025

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis (AD)

Summary

This is a single arm, and open-label phase I study

Eligibility

Min Age: 12 YearsMax Age: 18 Years

Inclusion Criteria3

When giving informed consent, the age range is 12-18 years old (including 12 years old), with no gender restrictions;
The subjects and their guardians voluntarily sign an informed consent form (dated), indicating that the subjects have been informed of all relevant parts of the study;
All women and all men with the potential to conceive must be willing to use at least one highly effective method of contraception from the time of signing the informed consent form until 3 months after the last administration of the investigational drug

Exclusion Criteria3

Subjects suspected to be allergic to VC005 gel or to excipients in VC005 gel, or with ≥ 2 kinds of drug allergy history in the past;
The researchers believe that there may be skin injuries or abnormalities in the subjects that could affect the evaluation of the administration site of the investigational drug；
The researchers believe that the subjects have clinically relevant skin diseases that are contraindicated in the study or affect the evaluation of the administration site, including but not limited to psoriasis, acne, dysplastic nevi, and skin cancer;

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVC005

VC005 with Local topical application

Locations(1)

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07329101

Related Trials

Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis

NCT073164651 location